HC Wainwright Issues Optimistic Outlook for OLMA Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Analysts at HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for Olema Pharmaceuticals in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.59) per share for the quarter, up from their previous estimate of ($0.64). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.03) EPS, FY2026 earnings at ($3.86) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($3.10) EPS.

Separately, Oppenheimer restated an “outperform” rating and issued a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday.

Olema Pharmaceuticals Trading Up 2.7 %

Shares of NASDAQ OLMA opened at $4.23 on Friday. The business has a fifty day simple moving average of $5.09 and a 200 day simple moving average of $8.35. The firm has a market capitalization of $242.37 million, a price-to-earnings ratio of -1.93 and a beta of 2.11. Olema Pharmaceuticals has a one year low of $3.94 and a one year high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.12.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of OLMA. KLP Kapitalforvaltning AS acquired a new position in Olema Pharmaceuticals during the fourth quarter worth $30,000. Hsbc Holdings PLC acquired a new position in Olema Pharmaceuticals during the fourth quarter worth $58,000. Teacher Retirement System of Texas bought a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth $60,000. Vontobel Holding Ltd. bought a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth $62,000. Finally, Virtus ETF Advisers LLC grew its holdings in shares of Olema Pharmaceuticals by 43.1% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company’s stock worth $62,000 after purchasing an additional 3,185 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Olema Pharmaceuticals

In related news, major shareholder Bain Capital Life Sciences Inv acquired 300,000 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was purchased at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the purchase, the insider now directly owns 7,800,000 shares of the company’s stock, valued at $44,928,000. The trade was a 4.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 19.40% of the stock is currently owned by corporate insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.